{"id":"heparin-anticoagulation","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":"0.5–3","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Heparin is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically increases its ability to inhibit thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the extension of existing thrombi. Heparin is used for both treatment and prevention of thrombotic events.","oneSentence":"Heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:32.746Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention and treatment of venous thromboembolism"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation with thromboembolism risk"},{"name":"Prevention of clotting during hemodialysis and extracorporeal circulation"}]},"trialDetails":[{"nctId":"NCT04790370","phase":"PHASE4","title":"Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-08-02","conditions":"Pulmonary Embolism","enrollment":544},{"nctId":"NCT07492901","phase":"NA","title":"Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2024-01-11","conditions":"Post Operative Arrythmia","enrollment":220},{"nctId":"NCT06753786","phase":"NA","title":"Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2024-10-21","conditions":"Venous Thromboembolism, Pulmonary Embolism, Intracerebral Hemorrhage","enrollment":200},{"nctId":"NCT05900388","phase":"","title":"A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-09-01","conditions":"Venous Thromboembolism, Children Under 2 Years","enrollment":850},{"nctId":"NCT07477977","phase":"NA","title":"Dose for Reversal of Heparin After Cardiopulmonary Bypass","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03-01","conditions":"Open Heart Surgery","enrollment":195},{"nctId":"NCT07467889","phase":"","title":"Impact of CRRT on Serum Carnitine and Micronutrient Levels","status":"COMPLETED","sponsor":"Gulhane Training and Research Hospital","startDate":"2023-01-01","conditions":"Acute Kidney Injury (Nontraumatic), Critical Illness","enrollment":43},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT03297281","phase":"NA","title":"Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)","status":"RECRUITING","sponsor":"Clinique Pasteur","startDate":"2017-10-30","conditions":"Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction","enrollment":389},{"nctId":"NCT06055920","phase":"NA","title":"The PEERLESS II Study","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-11-17","conditions":"Pulmonary Embolism","enrollment":1200},{"nctId":"NCT03041805","phase":"","title":"Caprini Score in Venous Surgery: a Prospective Cohort Study","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2017-01-01","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":3000},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07326215","phase":"NA","title":"A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+","status":"RECRUITING","sponsor":"Vantive Health LLC","startDate":"2025-12-11","conditions":"Acute Respiratory Distress Syndrome, Acute Kidney Injury","enrollment":99},{"nctId":"NCT07404345","phase":"PHASE4","title":"Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)","status":"NOT_YET_RECRUITING","sponsor":"Hospital Civil de Guadalajara","startDate":"2026-03-01","conditions":"Hemodialysis Access Failure, Kidney Disease, End-Stage, Hemodialysis Catheter","enrollment":54},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT05701917","phase":"NA","title":"DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-01-06","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome","enrollment":300},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT04496362","phase":"PHASE4","title":"Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor Research Institute","startDate":"2018-10-10","conditions":"ECMO, Heparin, Respiratory Failure","enrollment":100},{"nctId":"NCT07374978","phase":"NA","title":"Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-07-01","conditions":"Pulmonary Embolism Subacute Massive, Thrombolytic Therapy","enrollment":100},{"nctId":"NCT06080074","phase":"PHASE2","title":"Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-04-15","conditions":"Heart Failure, Cardiogenic Shock, Congenital Heart Disease","enrollment":50},{"nctId":"NCT07365644","phase":"","title":"Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier le Mans","startDate":"2026-01-01","conditions":"Prophylactic Anticoagulation","enrollment":1111},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT04273607","phase":"PHASE2, PHASE3","title":"Anticoagulation-free VV ECMO for Acute Respiratory Failure","status":"RECRUITING","sponsor":"Damian Ratano","startDate":"2022-09-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":40},{"nctId":"NCT04268940","phase":"","title":"Thrombo-Elastography Guided Management of ECMO","status":"COMPLETED","sponsor":"Damian Ratano","startDate":"2020-06-03","conditions":"Extracorporeal Circulation of Blood; Thrombocytopenia","enrollment":61},{"nctId":"NCT07342127","phase":"","title":"Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-01","conditions":"Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy","enrollment":100},{"nctId":"NCT05089227","phase":"PHASE2","title":"Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-02-03","conditions":"Prolonged Anticoagulation, Venous Thromboembolic Disease, Autoimmune Hemolytic Anemia","enrollment":72},{"nctId":"NCT05255003","phase":"PHASE4","title":"STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","status":"RECRUITING","sponsor":"Tzu-Fei Wang","startDate":"2022-08-29","conditions":"Cancer-associated Thrombosis, Thrombocytopenia","enrollment":50},{"nctId":"NCT03842657","phase":"PHASE2","title":"Regional Anticoagulation of Dialysis Circuits With a Calcium-free Citrate-containing Dialysate","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2019-07-05","conditions":"Hemodialysis Complication, Bleeding","enrollment":97},{"nctId":"NCT06628778","phase":"PHASE3","title":"Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2026-10-31","conditions":"Venous Thromboembolism (VTE)","enrollment":802},{"nctId":"NCT06329921","phase":"NA","title":"Inpatient Monitoring of Unfractionated Heparin","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2024-06-26","conditions":"Blood Clot, Thrombosis","enrollment":2000},{"nctId":"NCT03562754","phase":"NA","title":"Control Trial of Intermittent Hemodialysis With Regional Citrate VS Priming Heparin With Predilution in Patients at Risk of Bleeding","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2019-03-11","conditions":"Hemodialysis","enrollment":60},{"nctId":"NCT06640114","phase":"NA","title":"Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2024-10-22","conditions":"Psoriasis","enrollment":60},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT07234383","phase":"PHASE1","title":"Accelerated HEmodiafiltration in Severe Acute Diquat (AHEAD) Poisoning","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-01-01","conditions":"Diquat Poisoning","enrollment":24},{"nctId":"NCT06966765","phase":"PHASE3","title":"Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute Diquat Poisoning","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2027-01-01","conditions":"Diquat Poisoning","enrollment":267},{"nctId":"NCT05684796","phase":"NA","title":"Comparison of Two Pulmonary Embolism Treatments","status":"COMPLETED","sponsor":"Penumbra Inc.","startDate":"2023-11-27","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT04861103","phase":"PHASE4","title":"Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-10-01","conditions":"Pregnancy, High Risk, Anticoagulants","enrollment":12},{"nctId":"NCT06150742","phase":"NA","title":"Nafamostat Efficacy in Phase 3 Registrational CRRT Study","status":"RECRUITING","sponsor":"Talphera, Inc","startDate":"2024-08-15","conditions":"Acute Kidney Injury","enrollment":70},{"nctId":"NCT07214103","phase":"PHASE2","title":"Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-03-01","conditions":"Septic Shock, Coagulopathy","enrollment":120},{"nctId":"NCT04617093","phase":"NA","title":"Post-Market Study of Low-flow ECCO2R Using PrismaLung+","status":"COMPLETED","sponsor":"Vantive Health LLC","startDate":"2021-04-30","conditions":"Mild to Moderate Acute Respiratory Distress Syndrome","enrollment":63},{"nctId":"NCT06276010","phase":"NA","title":"Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO","status":"RECRUITING","sponsor":"Xiaotong Hou","startDate":"2024-07-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":80},{"nctId":"NCT06275555","phase":"NA","title":"Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation","status":"RECRUITING","sponsor":"Xiaotong Hou","startDate":"2024-06-03","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":154},{"nctId":"NCT07127718","phase":"PHASE2","title":"Preventive Strategies for Early and Late Complications of Leptospirosis","status":"RECRUITING","sponsor":"National Kidney and Transplant Institute, Philippines","startDate":"2024-04-12","conditions":"Leptospirosis","enrollment":678},{"nctId":"NCT05984537","phase":"PHASE4","title":"A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2023-07-01","conditions":"Coronary Microvascular Dysfunction","enrollment":70},{"nctId":"NCT05841498","phase":"NA","title":"Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome","status":"COMPLETED","sponsor":"University Medical Center Mainz","startDate":"2023-05-08","conditions":"Post-COVID-19 Syndrome, Post-COVID Syndrome, Post COVID-19 Condition","enrollment":40},{"nctId":"NCT05484830","phase":"NA","title":"Coagulation in Acute Aortic Dissection","status":"COMPLETED","sponsor":"Ivy susanne Modrau, MD","startDate":"2022-11-01","conditions":"Acute Aortic Dissection, Coagulation Disorder","enrollment":26},{"nctId":"NCT07032025","phase":"EARLY_PHASE1","title":"Mechanical Thrombectomy for Acute Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Pulmonary Embolism","enrollment":200},{"nctId":"NCT04997265","phase":"NA","title":"Strategies for Anticoagulation During Venovenous ECMO","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-12","conditions":"Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism","enrollment":26},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT06955936","phase":"NA","title":"Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Efferon JSC","startDate":"2025-04-29","conditions":"Myocardial Infarction, Cardiogenic Shock","enrollment":60},{"nctId":"NCT06369064","phase":"NA","title":"Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2024-07-03","conditions":"Acute Kidney Injury, Continuous Renal Replacement Therapy, Intensive Care Unit","enrollment":80},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT04536272","phase":"PHASE3","title":"Reduced Anticoagulation Targets in ECLS (RATE)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-10-01","conditions":"Heart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation","enrollment":330},{"nctId":"NCT04903262","phase":"NA","title":"Ultra-Protective Lung Ventilation With Extracorporeal CO2 Removal for Moderate ARDS","status":"RECRUITING","sponsor":"University of Bologna","startDate":"2024-12-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":230},{"nctId":"NCT04645550","phase":"PHASE4","title":"Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2020-11-22","conditions":"Cirrhosis, Splenectomy; Status, Venous Thrombosis","enrollment":120},{"nctId":"NCT01181544","phase":"NA","title":"A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis","status":"COMPLETED","sponsor":"Vantive Health LLC","startDate":"2011-03","conditions":"Renal Failure Chronic Requiring Hemodialysis","enrollment":5},{"nctId":"NCT01130025","phase":"PHASE3","title":"Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-08","conditions":"Venous Thromboembolism","enrollment":900},{"nctId":"NCT06833827","phase":"NA","title":"'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-02","conditions":"Pulmonary Embolism Acute","enrollment":111},{"nctId":"NCT06807905","phase":"PHASE4","title":"Efficiency and Biocompatibility in Hemodiafiltration Procedure","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2019-02-01","conditions":"End Stage Renal Disease on Dialysis, Biocompatibility, Anticoagulation","enrollment":20},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT06795698","phase":"PHASE2","title":"The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2019-03-01","conditions":"Fractures, Bone, CKD Stage 4, CKD Stage 3","enrollment":61},{"nctId":"NCT06779162","phase":"","title":"ROTEM-based Optimization of Anticoagulation Regimens in Lung Transplantation","status":"COMPLETED","sponsor":"University Hospital, Motol","startDate":"2022-01-01","conditions":"Anticoagulation, Lung Transplantation, Viscoelastic Properties","enrollment":65},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT04367831","phase":"PHASE4","title":"Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-05-02","conditions":"COVID-19, Venous Thromboses, Arterial Thrombosis","enrollment":94},{"nctId":"NCT06079021","phase":"NA","title":"COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2024-06-08","conditions":"Acute-On-Chronic Liver Failure, Anticoagulant Adverse Reaction, Sarcopenia","enrollment":20},{"nctId":"NCT06715930","phase":"","title":"Nomogram for Predicting In-stent Stenosis After Pipeline Embolization Device Treatment in Patients with Intracranial Aneurysm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2016-04-01","conditions":"Intracranial Aneurysm","enrollment":1500},{"nctId":"NCT06676085","phase":"NA","title":"A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation","status":"RECRUITING","sponsor":"Beijing Chao Yang Hospital","startDate":"2024-11-01","conditions":"ECMO","enrollment":60},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT02464969","phase":"PHASE4","title":"Apixaban for the Acute Treatment of Venous Thromboembolism in Children","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-22","conditions":"Venous Thromboembolism","enrollment":229},{"nctId":"NCT06224140","phase":"NA","title":"Heparin-Free Chronic HemoDialysis Assessment","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-06-06","conditions":"End-Stage Renal Disease","enrollment":100},{"nctId":"NCT06646328","phase":"PHASE4","title":"Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.","status":"TERMINATED","sponsor":"Fernando Sanchez","startDate":"2018-06-09","conditions":"Acute Kidney Injury","enrollment":20},{"nctId":"NCT03853005","phase":"NA","title":"Effect of High volumeHemodiafiltration on Lung Oxygenation","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-03-20","conditions":"Haemofiltration, Lung Mechanics, Septic Patients","enrollment":40},{"nctId":"NCT05959252","phase":"PHASE2","title":"BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation","status":"RECRUITING","sponsor":"Sydney Local Health District","startDate":"2024-05-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":80},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":"Cancer, Atrial Fibrillation","enrollment":""},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT06505616","phase":"NA","title":"SOLFA Study to Explore the Thrombogenicity of a Dialyzer","status":"COMPLETED","sponsor":"Fundación Senefro","startDate":"2022-01-17","conditions":"End Stage Renal Disease on Dialysis","enrollment":32},{"nctId":"NCT06504316","phase":"NA","title":"OXiris for Abdominal SEptic Shock (OASES Study)","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-08-15","conditions":"Septic Shock, Abdominal Sepsis, Multi Organ Failure","enrollment":192},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06487052","phase":"NA","title":"Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2024-01-10","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT02590783","phase":"NA","title":"Treatment of Pelvic Ring Fractures in the Elderly","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-10-17","conditions":"Pelvic Pain","enrollment":88},{"nctId":"NCT05148026","phase":"NA","title":"Regional Citrate Anticoagulation for RRT During V-V ECMO","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2021-11-14","conditions":"ARDS, Human, Acute Kidney Injury","enrollment":20},{"nctId":"NCT06375616","phase":"PHASE4","title":"Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI","status":"NOT_YET_RECRUITING","sponsor":"Shen Lei","startDate":"2024-04","conditions":"Sepsis","enrollment":156},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":"Venous Thromboembolism","enrollment":200},{"nctId":"NCT05006287","phase":"PHASE2","title":"The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Paul's Hospital, Canada","startDate":"2022-10-12","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT06365398","phase":"PHASE4","title":"Safety and Efficacy of Low-dose hEparinization in Cerebral Angiography sTudy","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2018-01-01","conditions":"Cerebral Angiography, Heparinization","enrollment":180},{"nctId":"NCT04925167","phase":"NA","title":"Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2021-07-06","conditions":"Respiratory Failure","enrollment":20},{"nctId":"NCT06319131","phase":"NA","title":"Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-05-01","conditions":"Portal Vein Thrombosis","enrollment":84},{"nctId":"NCT06038682","phase":"","title":"Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure","status":"COMPLETED","sponsor":"University Hospital Ostrava","startDate":"2020-04-01","conditions":"ARDS, COVID-19","enrollment":100},{"nctId":"NCT06285942","phase":"NA","title":"EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation","status":"UNKNOWN","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2024-02-01","conditions":"Atrial Fibrillation, Fragility","enrollment":168},{"nctId":"NCT02580773","phase":"PHASE3","title":"Therapeutic Anticoagulation Strategy for Acute Chest Syndrome","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-16","conditions":"Anemia, Sickle Cell, Acute Chest Syndrome","enrollment":198},{"nctId":"NCT04351438","phase":"","title":"Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2012-01-01","conditions":"Therapeutic Plasma Exchange, Anticoagulant Therapy","enrollment":108},{"nctId":"NCT02604238","phase":"PHASE3","title":"Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism","status":"WITHDRAWN","sponsor":"Azienda U.S.L. 1 di Massa e Carrara","startDate":"2016-03","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT04409834","phase":"PHASE4","title":"Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-08-05","conditions":"COVID-19, Venous Thromboembolism, Arterial Thrombosis","enrollment":390},{"nctId":"NCT05150938","phase":"","title":"A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-03-18","conditions":"Treatment of Venous Thromboembolism in Cancer Patients","enrollment":5737},{"nctId":"NCT05191290","phase":"PHASE4","title":"Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-01-21","conditions":"Apheresis, Anticoagulation","enrollment":15},{"nctId":"NCT06145269","phase":"EARLY_PHASE1","title":"Recanalization Rate of Acute DVT","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12-01","conditions":"Acute DVT of Lower Extremity","enrollment":100},{"nctId":"NCT05143567","phase":"NA","title":"Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications","status":"COMPLETED","sponsor":"Ryazan State Medical University","startDate":"2021-11-01","conditions":"Venous Thromboembolism, covid19, Thrombosis","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Heparin anticoagulation","genericName":"Heparin anticoagulation","companyName":"University Medical Centre Ljubljana","companyId":"university-medical-centre-ljubljana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Heparin anticoagulation is used to treat conditions such as blood clots, thrombosis, and cerebral venous thrombosis, as well as in patients with end-stage renal disease undergoing kidney replacement therapy. It works by activating Antithrombin-III, a protein that inhibits blood clot formation, through its oligosaccharide modality.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}